🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05988177
Starting soon Not applicable

Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections

NCT05988177 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Friendship Hospital
Phase
Not applicable
Started
2023-08-30
Last updated
2023-08-14

Condition(s) studied

Carbapenem Resistant Bacterial InfectionHemophagocytic Lymphohistiocytoses

Investigational drug(s) / intervention(s)

Carrimycin tablets

Carrimycin tablets: Carrimycin tablets are administered 400mg a day orally for 7 days.

Study summary

This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Met HLH-2004 diagnostic criteria; * Active infection; * Empirical treatment with carbapenems did not respond after 72 hours; * Age \>18 years old, no gender limitation; * Ability and willingness to adhere to the study visit schedule and all protocol requirements. Exclusion Criteria: * Other antibiotics should be selected according to the results of drug sensitivity; * Systemic antibiotics other than carbapenems are used with 72 hours; * Inability to take oral medications due to disease of gastrointestinal tract; * Severe liver insufficiency; * Expected survival time \< 1 month; * Pregnant or breasting-feeding women; * Allergic to Carrimycin tablets; * Active hepatitis B or hepatitis C infection; * Patients with HIV infection; * Patients with other contraindications considered unsuitable for participation in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Friendship Hospital, Capital Medical University Beijing Beijing Municipality

More Beijing Friendship Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05988177 on ClinicalTrials.gov ↗ ← All trials in China